VICO.ST STO
Vicore Pharma Holding AB (publ)
1W: -2.9%
1M: -14.5%
3M: -40.6%
YTD: -14.2%
1Y: -14.3%
3Y: -37.4%
5Y: -53.5%
kr 9.32 ($0.93)
-0.09 (-0.96%)
Weekly Expected Move ±5.1%
kr 8
kr 9
kr 9
kr 10
kr 10
Overview
Chart
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ETF Exposure
#7
of 48
Biotechnology
Technical Signal Map
2 Bullish
1 Neutral
10 Bearish
VICO.ST
$2.6B
Vicore Pharma Holding AB (publ)
BEARISH
-91
EGTX.ST
$4.4B
Egetis Therapeutics AB (publ)
BULLISH
+75
BRCTF
$3.3B
BioArctic AB (publ)
BULLISH
+35
CAMX.ST
$38B
Camurus AB
NEUTRAL
-1
BINV.ST
$1.5B
BioInvent International AB (publ)
LEAN BEAR
-14
GENO.ST
$1.3B
Genovis AB
LEAN BEAR
-19
SYNACT.ST
$910M
SynAct Pharma AB
LEAN BEAR
-26
HNSA.ST
$3.4B
Hansa Biopharma AB (publ)
BEARISH
-53
MVIR.ST
$990M
Medivir AB
BEARISH
-60
BIOA-B.ST
$27B
BioArctic AB
BEARISH
-75
FLERIE.ST
$1.4B
Flerie AB (publ)
BEARISH
-75
ALZCUR.ST
$950M
AlzeCure Pharma AB
BEARISH
-87
VCRE
$2.6B
Vicore Pharma Holding AB
BEARISH
-100
Peer Comparison
| Symbol | Mkt Cap | P/E | ROE % | ROIC % | Net Mgn % | Rev Grw % | Piotroski | Signal | 1Y Ret % |
|---|---|---|---|---|---|---|---|---|---|
| VICO.ST Vicore Pharma Holding AB (publ) | $2.6B | -4.9 | -53.8 | 789.8 | -6454.8 | -16.9 | 1 | BEARISH | -14.3 |
| EGTX.ST Egetis Therapeutics AB (publ) | $4.4B | -9.1 | -97.0 | -183.5 | -625.9 | 39.5 | 5 | BULLISH | 74.5 |
| BRCTF BioArctic AB (publ) | $3.3B | 256.5 | 5.2 | 77.4 | -4.5 | -46.1 | 3 | BULLISH | 17.6 |
| CAMX.ST Camurus AB | $38B | 53.4 | 15.9 | 89.6 | 34.3 | 0.0 | 6 | NEUTRAL | -13.7 |
| BINV.ST BioInvent International AB (publ) | $1.5B | -3.0 | -88.1 | 19974.7 | -964.0 | -87.2 | 1 | LEAN BEAR | -36.6 |
| GENO.ST Genovis AB | $1.3B | 65.1 | 7.5 | 7.1 | 3.8 | 11.2 | 4 | LEAN BEAR | -19.8 |
| SYNACT.ST SynAct Pharma AB | $910M | -9.0 | -51.7 | -56.7 | — | — | 3 | LEAN BEAR | -3.5 |
| HNSA.ST Hansa Biopharma AB (publ) | $3.4B | -4.2 | 160.2 | 1185.5 | -541.7 | -3.6 | 2 | BEARISH | 5.9 |
| MVIR.ST Medivir AB | $990M | — | — | — | — | — | — | BEARISH | — |
| BIOA-B.ST BioArctic AB | $27B | 256.5 | 5.2 | 77.8 | -4.5 | -46.1 | 3 | BEARISH | 29.9 |
| FLERIE.ST Flerie AB (publ) | $1.4B | -1.5 | -22.2 | -23.6 | 11550.0 | -195.5 | 1 | BEARISH | -61.9 |
| ALZCUR.ST AlzeCure Pharma AB | $950M | 45.9 | -433.7 | 255.5 | — | — | 1 | BEARISH | 71.5 |
| VCRE Vicore Pharma Holding AB | $2.6B | — | — | — | — | — | — | BEARISH | — |
| VICO.ST Vicore Pharma Holding AB (publ) | $2.6B | -4.9 | -53.8 | 789.8 | -6454.8 | -16.9 | 1 | BEARISH | -14.3 |
| EGTX.ST Egetis Therapeutics AB (publ) | $4.4B | -9.1 | -97.0 | -183.5 | -625.9 | 39.5 | 5 | BULLISH | 74.5 |
| BRCTF BioArctic AB (publ) | $3.3B | 256.5 | 5.2 | 77.4 | -4.5 | -46.1 | 3 | BULLISH | 17.6 |
| CAMX.ST Camurus AB | $38B | 53.4 | 15.9 | 89.6 | 34.3 | 0.0 | 6 | NEUTRAL | -13.7 |
| BINV.ST BioInvent International AB (publ) | $1.5B | -3.0 | -88.1 | 19974.7 | -964.0 | -87.2 | 1 | LEAN BEAR | -36.6 |
| GENO.ST Genovis AB | $1.3B | 65.1 | 7.5 | 7.1 | 3.8 | 11.2 | 4 | LEAN BEAR | -19.8 |
| SYNACT.ST SynAct Pharma AB | $910M | -9.0 | -51.7 | -56.7 | — | — | 3 | LEAN BEAR | -3.5 |
| HNSA.ST Hansa Biopharma AB (publ) | $3.4B | -4.2 | 160.2 | 1185.5 | -541.7 | -3.6 | 2 | BEARISH | 5.9 |
| MVIR.ST Medivir AB | $990M | — | — | — | — | — | — | BEARISH | — |
| BIOA-B.ST BioArctic AB | $27B | 256.5 | 5.2 | 77.8 | -4.5 | -46.1 | 3 | BEARISH | 29.9 |
| FLERIE.ST Flerie AB (publ) | $1.4B | -1.5 | -22.2 | -23.6 | 11550.0 | -195.5 | 1 | BEARISH | -61.9 |
| ALZCUR.ST AlzeCure Pharma AB | $950M | 45.9 | -433.7 | 255.5 | — | — | 1 | BEARISH | 71.5 |
| VCRE Vicore Pharma Holding AB | $2.6B | — | — | — | — | — | — | BEARISH | — |
Profile Radar
Valuation vs Profitability
Performance Comparison
Industry Market Share
VICO.ST vs Benchmarks
ROIC
Gross Margin
Op Margin
Net Margin
Revenue Growth
P/E Ratio
ROE
Piotroski F